
Jeplus.in
Purchase All Medicines.Get 10% Offer

Pharma Tech
Experts note that Democrats are likely to place Trumpâs MFN deals under the microscope and vie to reverse sweeping Medicaid cuts following the midterm results.

Pharma Tech
The collaboration will focus on antibody-drug conjugate (ADC) and T-cell engager (TCE) technologies across six programmes.

Pharma Tech
AbbVie will use the Oxford site to advance treatments for immunological, neurological and oncological diseases.

Pharma Tech
GEBRO Holding and Spektus Pharma have agreed a global commercialisation partnership for ActraFlex, an extended-release pain management therapy taken twice daily.

Pharma Tech
<p><!-- wp:paragraph --></p>
Sponsored content

Purchase All Medicines.Get 10% Offer
News
ET Pharma
Nov 4, 2026, 12:33 PM
Phatebo GmbH, founded in 2015, sources investigational, comparator and ancillary medicines, for innovators, and clinical research organisations.
Pharma Tech
Nov 4, 2026, 11:51 AM
Experts note that Democrats are likely to place Trumpâs MFN deals under the microscope and vie to reverse sweeping Medicaid cuts following the midterm results.
Pharma Tech
Nov 4, 2026, 11:39 AM
The collaboration will focus on antibody-drug conjugate (ADC) and T-cell engager (TCE) technologies across six programmes.
Pharma Tech
Nov 4, 2026, 11:36 AM
AbbVie will use the Oxford site to advance treatments for immunological, neurological and oncological diseases.
PharmaShots
Nov 4, 2026, 11:26 AM
Shots: The US FDA has granted Breakthrough Therapy Designation to Idorsiaâs daridorexant, a dual orexin receptor antagonist (DORA), for the treatment of insomnia disorder in pts aged 10 to <18yrs. The designation was supported by a P-II dose-finding study (n=165), which showed a significant dose-dependent improvement in total sleep time (p=0.0185); a single 50mg dose⊠The post Idorsia Receives the US FDAâs Breakthrough Therapy Designation for Daridorexant to Treat Pediatric Insomnia Disorder appeared first on PharmaShots.
PharmaShots
Nov 4, 2026, 11:21 AM
Shots: The US FDA has granted Fast Track Designation to Graviton BioScienceâs GV101, an oral, selective ROCK2 inhibitor, for the treatment of Friedreichâs ataxia (FA), following the recent clearance of its IND Graviton is initiating a 12wk., randomized, PBO-controlled, dose-finding P-II trial of GV101 in pts with FA, with first enrollment at US sites expected⊠The post Graviton BioScience Receives the US FDAâs Fast Track Designation for GV101 to Treat Friedreichâs Ataxia appeared first on PharmaShots.
News
Google News
Nov 4, 2026, 8:04 PM
What Does âCompromiseâ Mean for 340B Drug Pricing Program?  AIDS Healthcare Foundation
Google News
Nov 4, 2026, 7:54 PM
Teva Pharmaceutical Industries (NYSE:TEVA) Stock Gets Price Target Increase from TD Cowen  MarketBeat
Google News
Nov 4, 2026, 7:15 PM
Finnish biotech firm Volare targets full production at insect protein factory in 2027, unveils plans for second facility  SeafoodSource
Google News
Nov 4, 2026, 6:47 PM
Novoâs race to catch Eli Lilly may already be lost  Endpoints News
Google News
Nov 4, 2026, 6:45 PM
Boehringer forges $7bn alliance with China's SBP Group  pharmaphorum
Google News
Nov 4, 2026, 6:34 PM
Govt proposes immediate licence suspension for substandard drugmakers  Business Standard
Google News
Nov 4, 2026, 6:28 PM
Sun Pharmaceutical Industries sales rise 11.8% to INR161,000 million  Multibagg AI
Google News
Nov 4, 2026, 6:22 PM
India's first dengue vaccine due in 2027: Japanese pharma.  en.etemaaddaily.com
Google News
Nov 4, 2026, 5:50 PM
The Best Negotiation Training and Consulting Firms for Pharmaceutical, Biotech and Medical Device Companies in 2026Â Â The Canary
Sponsored placement

Purchase All Medicines.Get 10% Offer